In cancer, non-synonymous DNA base changes alter protein sequence and produce
neoantigens that are detected by the immune system. For immune detection, neoantigens …

Adoptive cell therapy (ACT) with tumor-specific T cells has been shown to mediate durable
cancer regression. Tumor-specific T cells are also the basis of other therapies, notably …

Genetic studies associate killer cell immunoglobulin-like receptors (KIRs) and their HLA
class I ligands with a variety of human diseases. The basis for these associations and the …

Human leukocyte antigen-G (HLA-G) is a non-classical human major histocompatibility
complex (MHC-I) molecule with the membrane-bound and soluble types. HLA-G is primarily …

Human leukocyte antigen (HLA) molecules and their relationships with natural killer (NK)
cells, specifically through their interaction with killer-cell immunoglobulin-like receptors …

HLA (HLA) are a major barrier to transplant success, as HLA‐A and‐B molecules are
principal ligands for T‐cells, and HLA‐C for Killer cell Immunoglobulin‐like Receptors (KIR) …

Peptides presented by class I major histocompatibility complex (MHC-I) proteins provide
biomarkers for therapeutic targeting using T cell receptors (TCRs), TCR-mimicking …

Mutations in KRAS are some of the most common across multiple cancer types and are thus
attractive targets for therapy. Recent studies demonstrated that mutant KRAS generates …